Comparing Nyvepria vs Orserdu
| Nyvepria (pegfilgrastim) | Orserdu (elacestrant) |
|
|---|
| Nyvepria (pegfilgrastim) | Orserdu (elacestrant) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Neutropenia Associated with Chemotherapy, Febrile Neutropenia. Nyvepria may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Breast Cancer. Orserdu may also be used for purposes not listed in this medication guide. |
||||||||||||||||
| More about Nyvepria (pegfilgrastim) | More about Orserdu (elacestrant) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Nyvepria side effects |
View all Orserdu side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Nyvepria prices |
View all Orserdu prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Other pegfilgrastim brands include: Fulphila, Fylnetra, Neulasta, Stimufend, Udenyca, Ziextenzo |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
80 hours |
50 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 178 drugs are known to interact with Nyvepria:
|
A total of 291 drugs are known to interact with Orserdu:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
N/A |
January 27, 2023 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Augmentin
Augmentin is a prescription antibiotic combining amoxicillin and clavulanate to treat bacterial ...
Cipro
Cipro (ciprofloxacin) is a fluoroquinolone antibiotic used to treat bacterial infections. Learn ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Zosyn
Zosyn is used to treat bacterial infections such as urinary tract and skin infections and ...
Zarxio
Zarxio (filgrastim-sndz) is biosimilar product used to treat neutropenia associated with ...
Maxipime
Maxipime is used for bacteremia, febrile neutropenia, intraabdominal infection, kidney infections ...
Neulasta
Neulasta is used to stimulate neutrophil growth and reduce infection risk (manifested by febrile ...
Vancocin
Vancocin is used for bacteremia, bacterial endocarditis prevention, bacterial infection, bone ...
Neupogen
Neupogen (filgrastim) is used to treat neutropenia, a lack of certain white blood cells caused by ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.